Ding J, Xu C, Xu M, He XY, Li WN, He F. Emerging role of engineered exosomes in nonalcoholic fatty liver disease. World J Hepatol 2023; 15(3): 386-392 [PMID: 37034232 DOI: 10.4254/wjh.v15.i3.386]
Corresponding Author of This Article
Fei He, PhD, Research Associate, Department of Hepatobiliary Surgery, Xi-Jing Hospital, No. 127 Changle West Road, Xi'an 710032, Shaanxi Province, China. hefei_hefei@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Ding J, Xu C, Xu M, He XY, Li WN, He F. Emerging role of engineered exosomes in nonalcoholic fatty liver disease. World J Hepatol 2023; 15(3): 386-392 [PMID: 37034232 DOI: 10.4254/wjh.v15.i3.386]
World J Hepatol. Mar 27, 2023; 15(3): 386-392 Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.386
Emerging role of engineered exosomes in nonalcoholic fatty liver disease
Jian Ding, Chen Xu, Ming Xu, Xiao-Yue He, Wei-Na Li, Fei He
Jian Ding, Chen Xu, Ming Xu, Department of Hepatobiliary Surgery, Xi-Jing Hospital, The Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China
Xiao-Yue He, The Affiliated Hospital of Jining Medical University, Jining Medical University, Jining 272067, Shandong Province, China
Wei-Na Li, School of Basic Medicine, The Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China
Fei He, Department of Hepatobiliary Surgery, Xi-Jing Hospital, Xi'an 710032, Shaanxi Province, China
Author contributions: Ding J contributed to writing the original draft; Xu C contributed to picture making; Xu M, He XY, and Li WN contributed to data collection; He F contributed to designed the review and revised the final version.
Supported byNational Natural Science Foundation of China, No. 81970535.
Conflict-of-interest statement: All the authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Corresponding author: Fei He, PhD, Research Associate, Department of Hepatobiliary Surgery, Xi-Jing Hospital, No. 127 Changle West Road, Xi'an 710032, Shaanxi Province, China. hefei_hefei@163.com
Received: December 26, 2022 Peer-review started: December 26, 2022 First decision: February 1, 2023 Revised: February 20, 2023 Accepted: March 15, 2023 Article in press: March 15, 2023 Published online: March 27, 2023 Processing time: 86 Days and 5.8 Hours
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. NAFLD comprises a continuum of liver abnormalities from nonalcoholic fatty liver to nonalcoholic steatohepatitis, and can even lead to cirrhosis and liver cancer. However, a well-established treatment for NAFLD has yet to be identified. Exosomes have become an ideal drug delivery tool because of their high transmissibility, low immunogenicity, easy accessibility and targeting. Exosomes with specific modifications, known as engineered exosomes, have the potential to treat a variety of diseases. Here, we review the treatment of NAFLD with engineered exosomes and the potential use of exosomes as biomarkers and therapeutic targets for NAFLD.
Core Tip: Nonalcoholic fatty liver disease (NAFLD) is the fastest growing chronic disease in the world. As the disease progresses, NAFLD can lead to liver fibrosis, cirrhosis and even liver cancer. However, a well-established treatment for NAFLD has yet to be identified. Exosomes are small extracellular vesicles secreted by cells. Owing to their high delivery efficiency and biocompatibility, exosomes are expected to become a new means of drug delivery and precise treatment for a variety of diseases, including NAFLD.
